News|Articles|November 18, 2026

White House Withdraws Heidi Overton's Nomination as FDA Commissioner

Listen
0:00 / 0:00

Key Takeaways

  • The nomination was pulled pre–HELP Committee vote after vote-counting suggested she could not secure the required Republican support to reach the full Senate.
  • Vaccine-related actions, particularly the push to split MMR and reduce routine childhood schedule coverage, amplified concerns about politicized decision-making amid a major measles outbreak.
SHOW MORE

The withdrawal came on the eve of a Senate committee vote, leaving the FDA without a nominee as vaccine and mifepristone debates continue.

The White House has withdrawn the nomination of Heidi Overton, MD, PhD, to serve as commissioner of the FDA, just before the Senate Health, Education, Labor, and Pensions (HELP) Committee was scheduled to vote on her confirmation Wednesday morning, according to The New York Times.1

Overton, a White House domestic policy adviser, would have needed the support of every Republican on the committee to advance to the full Senate. According to 2 people familiar with the decision, the White House concluded Tuesday night that she did not have enough votes. Axios was the first to report the withdrawal.1

Committee Chair Bill Cassidy, MD (R, Louisiana), disputed in a social media post Tuesday night, saying the White House had abandoned Overton. He wrote that he believed she would have passed out of committee and through the full Senate, and that his conversations with her had convinced him she would follow the science.1

President Donald Trump announced the nomination in August, praising Overton on Truth Social for her work alongside Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. and Mehmet Oz, MD, on his health agenda.2 She was reportedly Trump's third pick for the role following the May departure of former Commissioner Marty Makary.2,3

Vaccine Policy Shaped the Confirmation Fight

Overton's role in an August executive order to split the combination measles, mumps, and rubella (MMR) vaccine into 3 separate shots drew scrutiny from the start. Shortly after her nomination, Cassidy said her involvement in the order raised serious doubts about her candidacy, and at her September confirmation hearing, he pressed her repeatedly on whether she would stand up to the president on vaccines.1 Overton told the committee the measles vaccine is safe and effective, calling it "our best tool right now in the public health response to the measles outbreak."1

The order, which also sought to reduce the number of diseases covered by the routine childhood schedule from 18 to 11, was described by the American Academy of Pediatrics (AAP) as "not only disheartening but dangerous."2,3 Health experts have said the order sowed confusion among parents during the worst US measles outbreak in roughly 30 years, an outbreak that has led to the loss of the country’s measles elimination status.2 At the same hearing, Overton signaled loyalty to Trump, defending his involvement in decisions typically left to career scientists.1

The Politicization of Mifepristone

Abortion policy also weighed heavily on the nomination. Democrats were alarmed by Overton's past description of mifepristone as dangerous to women, and in a 2023 policy brief, she urged Congress to strictly regulate the drug.1,2 During her hearing, however, she testified that mifepristone is safe and effective as currently labeled under FDA regulations.1

Republicans, meanwhile, were concerned by her vague answers about an ongoing FDA safety review of mifepristone. According to Cassidy, anti-abortion senators sought final assurances from the administration on its commitment to their priorities on Tuesday, and the White House withdrew Overton instead.1 Reaction to the nomination had been divided from the outset, with Senator Patty Murray (D, Washington) pledging to vote against Overton and House Speaker Mike Johnson (R, Louisiana) praising her selection.3

What the Withdrawal Means for Pharmacists

The FDA regulates products that account for about 20% of US spending, including prescription and OTC medications, dietary supplements, cosmetics, and medical devices.1 It remains unclear whether the White House will name another nominee, and the window for confirmation is narrowing as Democrats prepare to take control of the Senate in January.1

For pharmacists, the continued leadership vacuum leaves several open questions. The agency's mifepristone review could affect rules that allow the drug to be mailed and dispensed via telehealth, and an ongoing FDA review of selective serotonin reuptake inhibitor use during pregnancy may shape how pharmacists counsel patients.3 Any federal move to split the MMR vaccine would also complicate inventory management and conversations with parents already navigating shifting guidance.3

As federal health leadership remains in flux, pharmacists will continue to serve as trusted, evidence-based resources for patients seeking clarity on vaccines, reproductive health medications, and other treatments under FDA oversight.3

READ MORE: FDA Updates Resource Center

REFERENCES
1. Jewett C. White House withdraws nomination of Heidi Overton to be F.D.A. commissioner. The New York Times. November 17, 2026. Accessed November 18, 2026. https://www.nytimes.com/2026/11/17/us/overton-fda-nomination-withdrawn.html
2. Glenza J. Trump nominates abortion opponent Heidi Overton to be head of FDA. The Guardian. August 19, 2026. Accessed November 18, 2026. https://www.theguardian.com/us-news/2026/aug/19/heidi-overton-fda-commissioner-nomination
3. Nowosielski B. The Trump Administration advisor set to become next FDA lead. Drug Topics. August 21, 2026. Accessed November 18, 2026. https://www.drugtopics.com/view/the-trump-administration-advisor-set-to-become-next-fda-lead

Related to this article